Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay

the CAPNETZ Study Group; Mathias W. Pletz; Santiago Ewig; Gernot Rohde; Hartwig Schuette; Jan Rupp; Tobias Welte; Norbert Suttorp; Christina Forstner; S. Krüger; D. Frechen; W. Knüppel; I. Armari; D. Stolz; N. Suttorp; H. Schütte; P. Creutz; T. Bauer; J. Hecht; W. Pankow; A. Lies; D. Thiemig; B. Hauptmeier; D. Wehde; M. Suermann; S. Ewig; M. Prediger; G. Zernia; J. Rademacher; M. Barten; G. Abrahamczik; J. Naim; W. Kröner; T.Illig; N. Klopp; C. Kroegel; M. Pletz; R. Bals; K. Dalhoff; S. Schütz; R. Hörster; G. Rohde; H. Petermann; W. Buschmann; R. Kröning; Y. Aydin; T. Schaberg; I. Hering; R. Marre; C. Schumann; H. von Baum

doi:10.1016/j.vaccine.2016.03.052

Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay

the CAPNETZ Study Group, Mathias W. Pletz, Santiago Ewig, Gernot Rohde, Hartwig Schuette, Jan Rupp, Tobias Welte, Norbert Suttorp, Christina Forstner^*, S. Krüger, D. Frechen, W. Knüppel, I. Armari, D. Stolz, N. Suttorp, H. Schütte, P. Creutz, T. Bauer, J. Hecht, W. PankowA. Lies, D. Thiemig, B. Hauptmeier, D. Wehde, M. Suermann, S. Ewig, M. Prediger, G. Zernia, J. Rademacher, M. Barten, G. Abrahamczik, J. Naim, W. Kröner, T.Illig, N. Klopp, C. Kroegel, M. Pletz, R. Bals, K. Dalhoff, S. Schütz, R. Hörster, G. Rohde, H. Petermann, W. Buschmann, R. Kröning, Y. Aydin, T. Schaberg, I. Hering, R. Marre, C. Schumann, H. von Baum

^*Korrespondierende/r Autor/-in für diese Arbeit

34 Zitate (Scopus)

Abstract

The aim of the study was to compare the distribution of the vaccine-serotypes covered by pneumococcal conjugate vaccines (PCV7 and PCV13) in adult patients with pneumococcal community-acquired pneumonia in Germany between the periods 2002-2006 and 2007-2011 using a novel serotype-specific multiplex urinary antigen detection assay (SSUA). Vaccination of children started with PCV7 in 2007, which was replaced by PCV13 in 2010. Following confirmation of the accuracy of SSUA in long-term stored urine samples from 112 patients with confirmed pneumonia and known pneumococcal serotype, urine samples of 391 CAPNETZ patients with documented pneumococcal pneumonia (i.e. positive BinaxNOW^®Streptococcus pneumoniae urine antigen test) but unknown serotype were tested for the 13 vaccine-serotypes using SSUA. The proportion of PCV7-serotypes significantly decreased in adult patients with pneumonia from 30.6% (2002-6) to 13.3% (2007-11, p < 0.001); in bacteremic pneumonia, PCV7-serotypes completely disappeared (3/14 versus 0/19, p = 0.058). Conversely, pneumococcal serotypes included by PCV13 remained stable during study period with a coverage of 61.5% (2002-06) and 59.7% (2007-11) in non-bacteremic pneumonia and 79% (for both periods) in bacteremic pneumonia, mainly due to an increase in pneumococcal serotypes 1, 3 and 7F during the second period. Thus, implementation of PCV7 in children in Germany in 2007 was associated with a significant decrease in vaccine-serotypes covered by PCV7 in adult patients with non-bacteremic pneumococcal pneumonia and with an elimination of PCV7 vaccine-serotypes in bacteremic pneumococcal pneumonia. PCV13 coverage remained high up to 2011, mainly due to an increase in serotypes 1, 3 and 7F.German Clinical Trials Register: DRKS00005274.

Originalsprache	Englisch
Zeitschrift	Vaccine
Jahrgang	34
Ausgabenummer	20
Seiten (von - bis)	2342-2348
Seitenumfang	7
ISSN	0264-410X
DOIs	https://doi.org/10.1016/j.vaccine.2016.03.052
Publikationsstatus	Veröffentlicht - 29.04.2016

Fördermittel

Members of the CAPNETZ study groups: S. Krüger, D. Frechen (Medical Clinic I, University Clinic RWTH Aachen); W. Knüppel, I. Armari (Clinic for Internal Medicine, Hospital Bad Arolsen); D. Stolz (Clinic for Pneumology, Uni-Spital, Basel); N. Suttorp, H. Schütte, P. Creutz (Department of Infectious Disease and Respiratory Medicine, Charité-University Medicine, Berlin); T. Bauer, J. Hecht (HELIOS Klinikum Emil von Behring, Berlin); W. Pankow, A. Lies, D. Thiemig (Clinic for Internal Medicine – Pneumology and Infektiology – Vivantes Clinical Center, Berlin-Neukölln); B. Hauptmeier, D. Wehde, M. Suermann (University Hospital Bergmannsheil, Dept. of Pneumology, Allergology and Sleep Medicine, Bochum); S. Ewig (Department of Respiratory Medicine and Infectious Diseases, Augusta Hospital, Bochum); M. Prediger, G. Zernia (III. Medical Clinic, Carl-Thiem-Klinikum Cottbus); T. Welte, J. Rademacher (Department of Respiratory Medicine, Hannover Medical School, Hanover); G. Barten, M. Abrahamczik, J. Naim, W. Kröner (Main Office, Hannover); T. Illig, N. Klopp (Hannover Unified Biobank); C. Kroegel (Dept. of Cardiology, Angiology, Pneumology, Internal Intensive Care Medicine, University Hospital Jena); M. Pletz (Dept. of Gastroenterology, Hepatology and Infectious Diseases, University Hospital, Jena); R. Bals (University Clinic Saarlandes, Internal Medicine V – Pneumology, Homburg/Saar); K. Dalhoff, S. Schütz, R. Hörster (Med. Clinic III, Pulmonology, University Clinic Schleswig-Holstein, Lübeck); G. Rohde (Department of Respiratory Medicine, Maastricht University Medical Center – MUMC+, Maastricht, The Netherlands); W. Petermann, H. Buschmann, R. Kröning, Y. Aydin (Brotherhospital St. Josef, Medical Clinic – Pneumology, Paderborn); T. Schaberg, I. Hering (Center of Pneumology, Diakonie-Hospital Rotenburg); R. Marre (University of Ulm); C. Schumann (Department of Internal Medicine II, University of Ulm); H. von Baum (Ulm University Hospital, Med. Microbiology and Hygiene); T. Illmann, M. Wallner (2mt Software, Ulm); O. Burghuber, G. Rainer (Internal Lung Department, Otto Wagner Spital Wien) and all study nurses. Author contributions: MWP and CF designed and performed the study and analyzed the data. SE, GR, HS, JR, TW and NS were major contributors in drafting the manuscript. All authors have approved the final version of the manuscript. Conflict of interest: MWP is a consultant to and a member of the speakers’ bureaus for Pfizer, GSK and MSD, and has received research grants from Pfizer. SE is a consultant to and a member of the speakers’ bureaus for Pfizer. TW is the head of clinical studies and a member of the speakers’ bureaus for Pfizer, GSK and MSD and is a consultant to Pfizer and MSD. GR is a consultant to and a member of the speaker’ bureaus for Pfizer, Novartis, Chiesi and Astra-Zeneca. CF is a member of the speakers’ bureau for Pfizer and MSD. HS, JR and NS declare no conflicts of interest. Funding: CAPNETZ was funded by a German Federal Ministry of Education and Research grant [ 01KI07145 ] 2001–2011. MWP and CF were supported by a grant from the German Federal Ministry of Education and Research ( BMBF ); grant number [ 01KI1204 ]. This study was supported by an unrestricted grant from Pfizer.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen
SDG 10 – Weniger Ungleichheiten

Strategische Forschungsbereiche und Zentren

Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)

Dokumente

10.1016/j.vaccine.2016.03.052

Weitere Links

Link to publication in Scopus

Zitieren

the CAPNETZ Study Group, Pletz, M. W., Ewig, S., Rohde, G., Schuette, H., Rupp, J., Welte, T., Suttorp, N., Forstner, C., Krüger, S., Frechen, D., Knüppel, W., Armari, I., Stolz, D., Suttorp, N., Schütte, H., Creutz, P., Bauer, T., Hecht, J., ... von Baum, H. (2016). Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay. Vaccine, 34(20), 2342-2348. https://doi.org/10.1016/j.vaccine.2016.03.052

@article{5754fef2935e4c1797ec2cab61b97f64,

title = "Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay",

abstract = "The aim of the study was to compare the distribution of the vaccine-serotypes covered by pneumococcal conjugate vaccines (PCV7 and PCV13) in adult patients with pneumococcal community-acquired pneumonia in Germany between the periods 2002-2006 and 2007-2011 using a novel serotype-specific multiplex urinary antigen detection assay (SSUA). Vaccination of children started with PCV7 in 2007, which was replaced by PCV13 in 2010. Following confirmation of the accuracy of SSUA in long-term stored urine samples from 112 patients with confirmed pneumonia and known pneumococcal serotype, urine samples of 391 CAPNETZ patients with documented pneumococcal pneumonia (i.e. positive BinaxNOW{\textregistered}Streptococcus pneumoniae urine antigen test) but unknown serotype were tested for the 13 vaccine-serotypes using SSUA. The proportion of PCV7-serotypes significantly decreased in adult patients with pneumonia from 30.6\% (2002-6) to 13.3\% (2007-11, p < 0.001); in bacteremic pneumonia, PCV7-serotypes completely disappeared (3/14 versus 0/19, p = 0.058). Conversely, pneumococcal serotypes included by PCV13 remained stable during study period with a coverage of 61.5\% (2002-06) and 59.7\% (2007-11) in non-bacteremic pneumonia and 79\% (for both periods) in bacteremic pneumonia, mainly due to an increase in pneumococcal serotypes 1, 3 and 7F during the second period. Thus, implementation of PCV7 in children in Germany in 2007 was associated with a significant decrease in vaccine-serotypes covered by PCV7 in adult patients with non-bacteremic pneumococcal pneumonia and with an elimination of PCV7 vaccine-serotypes in bacteremic pneumococcal pneumonia. PCV13 coverage remained high up to 2011, mainly due to an increase in serotypes 1, 3 and 7F.German Clinical Trials Register: DRKS00005274.",

author = "\{the CAPNETZ Study Group\} and Pletz, \{Mathias W.\} and Santiago Ewig and Gernot Rohde and Hartwig Schuette and Jan Rupp and Tobias Welte and Norbert Suttorp and Christina Forstner and S. Kr{\"u}ger and D. Frechen and W. Kn{\"u}ppel and I. Armari and D. Stolz and N. Suttorp and H. Sch{\"u}tte and P. Creutz and T. Bauer and J. Hecht and W. Pankow and A. Lies and D. Thiemig and B. Hauptmeier and D. Wehde and M. Suermann and S. Ewig and M. Prediger and G. Zernia and J. Rademacher and M. Barten and G. Abrahamczik and J. Naim and W. Kr{\"o}ner and T.Illig and N. Klopp and C. Kroegel and M. Pletz and R. Bals and K. Dalhoff and S. Sch{\"u}tz and R. H{\"o}rster and G. Rohde and H. Petermann and W. Buschmann and R. Kr{\"o}ning and Y. Aydin and T. Schaberg and I. Hering and R. Marre and C. Schumann and \{von Baum\}, H.",

year = "2016",

month = apr,

day = "29",

doi = "10.1016/j.vaccine.2016.03.052",

language = "English",

volume = "34",

pages = "2342--2348",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd",

number = "20",

}

the CAPNETZ Study Group, Pletz, MW, Ewig, S, Rohde, G, Schuette, H, Rupp, J, Welte, T, Suttorp, N, Forstner, C, Krüger, S, Frechen, D, Knüppel, W, Armari, I, Stolz, D, Suttorp, N, Schütte, H, Creutz, P, Bauer, T, Hecht, J, Pankow, W, Lies, A, Thiemig, D, Hauptmeier, B, Wehde, D, Suermann, M, Ewig, S, Prediger, M, Zernia, G, Rademacher, J, Barten, M, Abrahamczik, G, Naim, J, Kröner, W, T.Illig, Klopp, N, Kroegel, C, Pletz, M, Bals, R, Dalhoff, K, Schütz, S, Hörster, R, Rohde, G, Petermann, H, Buschmann, W, Kröning, R, Aydin, Y, Schaberg, T, Hering, I, Marre, R, Schumann, C & von Baum, H 2016, 'Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay', Vaccine, Jg. 34, Nr. 20, S. 2342-2348. https://doi.org/10.1016/j.vaccine.2016.03.052

Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay. / the CAPNETZ Study Group; Pletz, Mathias W.; Ewig, Santiago et al.
in: Vaccine, Jahrgang 34, Nr. 20, 29.04.2016, S. 2342-2348.

Publikation: Beiträge in Fachzeitschriften › Zeitschriftenaufsätze › Forschung › Begutachtung

TY - JOUR

T1 - Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay

AU - the CAPNETZ Study Group

AU - Pletz, Mathias W.

AU - Ewig, Santiago

AU - Rohde, Gernot

AU - Schuette, Hartwig

AU - Rupp, Jan

AU - Welte, Tobias

AU - Suttorp, Norbert

AU - Forstner, Christina

AU - Krüger, S.

AU - Frechen, D.

AU - Knüppel, W.

AU - Armari, I.

AU - Stolz, D.

AU - Suttorp, N.

AU - Schütte, H.

AU - Creutz, P.

AU - Bauer, T.

AU - Hecht, J.

AU - Pankow, W.

AU - Lies, A.

AU - Thiemig, D.

AU - Hauptmeier, B.

AU - Wehde, D.

AU - Suermann, M.

AU - Ewig, S.

AU - Prediger, M.

AU - Zernia, G.

AU - Rademacher, J.

AU - Barten, M.

AU - Abrahamczik, G.

AU - Naim, J.

AU - Kröner, W.

AU - T.Illig,

AU - Klopp, N.

AU - Kroegel, C.

AU - Pletz, M.

AU - Bals, R.

AU - Dalhoff, K.

AU - Schütz, S.

AU - Hörster, R.

AU - Rohde, G.

AU - Petermann, H.

AU - Buschmann, W.

AU - Kröning, R.

AU - Aydin, Y.

AU - Schaberg, T.

AU - Hering, I.

AU - Marre, R.

AU - Schumann, C.

AU - von Baum, H.

PY - 2016/4/29

Y1 - 2016/4/29

N2 - The aim of the study was to compare the distribution of the vaccine-serotypes covered by pneumococcal conjugate vaccines (PCV7 and PCV13) in adult patients with pneumococcal community-acquired pneumonia in Germany between the periods 2002-2006 and 2007-2011 using a novel serotype-specific multiplex urinary antigen detection assay (SSUA). Vaccination of children started with PCV7 in 2007, which was replaced by PCV13 in 2010. Following confirmation of the accuracy of SSUA in long-term stored urine samples from 112 patients with confirmed pneumonia and known pneumococcal serotype, urine samples of 391 CAPNETZ patients with documented pneumococcal pneumonia (i.e. positive BinaxNOW®Streptococcus pneumoniae urine antigen test) but unknown serotype were tested for the 13 vaccine-serotypes using SSUA. The proportion of PCV7-serotypes significantly decreased in adult patients with pneumonia from 30.6% (2002-6) to 13.3% (2007-11, p < 0.001); in bacteremic pneumonia, PCV7-serotypes completely disappeared (3/14 versus 0/19, p = 0.058). Conversely, pneumococcal serotypes included by PCV13 remained stable during study period with a coverage of 61.5% (2002-06) and 59.7% (2007-11) in non-bacteremic pneumonia and 79% (for both periods) in bacteremic pneumonia, mainly due to an increase in pneumococcal serotypes 1, 3 and 7F during the second period. Thus, implementation of PCV7 in children in Germany in 2007 was associated with a significant decrease in vaccine-serotypes covered by PCV7 in adult patients with non-bacteremic pneumococcal pneumonia and with an elimination of PCV7 vaccine-serotypes in bacteremic pneumococcal pneumonia. PCV13 coverage remained high up to 2011, mainly due to an increase in serotypes 1, 3 and 7F.German Clinical Trials Register: DRKS00005274.

AB - The aim of the study was to compare the distribution of the vaccine-serotypes covered by pneumococcal conjugate vaccines (PCV7 and PCV13) in adult patients with pneumococcal community-acquired pneumonia in Germany between the periods 2002-2006 and 2007-2011 using a novel serotype-specific multiplex urinary antigen detection assay (SSUA). Vaccination of children started with PCV7 in 2007, which was replaced by PCV13 in 2010. Following confirmation of the accuracy of SSUA in long-term stored urine samples from 112 patients with confirmed pneumonia and known pneumococcal serotype, urine samples of 391 CAPNETZ patients with documented pneumococcal pneumonia (i.e. positive BinaxNOW®Streptococcus pneumoniae urine antigen test) but unknown serotype were tested for the 13 vaccine-serotypes using SSUA. The proportion of PCV7-serotypes significantly decreased in adult patients with pneumonia from 30.6% (2002-6) to 13.3% (2007-11, p < 0.001); in bacteremic pneumonia, PCV7-serotypes completely disappeared (3/14 versus 0/19, p = 0.058). Conversely, pneumococcal serotypes included by PCV13 remained stable during study period with a coverage of 61.5% (2002-06) and 59.7% (2007-11) in non-bacteremic pneumonia and 79% (for both periods) in bacteremic pneumonia, mainly due to an increase in pneumococcal serotypes 1, 3 and 7F during the second period. Thus, implementation of PCV7 in children in Germany in 2007 was associated with a significant decrease in vaccine-serotypes covered by PCV7 in adult patients with non-bacteremic pneumococcal pneumonia and with an elimination of PCV7 vaccine-serotypes in bacteremic pneumococcal pneumonia. PCV13 coverage remained high up to 2011, mainly due to an increase in serotypes 1, 3 and 7F.German Clinical Trials Register: DRKS00005274.

UR - https://www.scopus.com/pages/publications/84962289408

U2 - 10.1016/j.vaccine.2016.03.052

DO - 10.1016/j.vaccine.2016.03.052

M3 - Journal articles

C2 - 27016653

AN - SCOPUS:84962289408

SN - 0264-410X

VL - 34

SP - 2342

EP - 2348

JO - Vaccine

JF - Vaccine

IS - 20

ER -

Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay

Abstract

Fördermittel

UN SDGs

Strategische Forschungsbereiche und Zentren

Dokumente

Weitere Links

Fingerprint

Zitieren